Moneycontrol Presented by Motilal Oswal
Days hours minutes
Nerolac
Presented by :

Co-Presenting Sponsor :

Capital Trade

Powered by :

Godrej Properties

Associate Sponsors :

Aegon Life
LIC Housing Finance
Indiabulls

Co-Presenting Sponsor

Capital Trade

Associate Sponsors

  • Indiabulls
  • Aegon Life
  • Image 3
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Aurobindo Pharma

Aurobindo Pharma

BSE: 524804|NSE: AUROPHARMA|ISIN: INE406A01037|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jan 16, 15:40
641.95
-16 (-2.43%)
VOLUME 143,778
LIVE
NSE
Jan 16, 15:59
641.10
-16.9 (-2.57%)
VOLUME 2,167,758
News on Aurobindo Pharma
Select Year: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Sell Aurobindo Pharma, Coal India; Buy Gati: Ashwani Gujral 

3.15 pm | 16 Jan 2018 |  Source: CNBC-TV18

Ashwani Gujral of ashwanigujral.com is of the view that one may sell Aurobindo Pharma and Coal India....

Buy Zee Entertainment Enterprises; sell Aurobindo Pharma: Mitessh Thakkar 

3.46 pm | 15 Jan 2018 |  Source: CNBC-TV18

Mitessh Thakkar of mitesshthakkar.com suggests selling Aurobindo Pharma....

Will Europe buyouts help Indian drug makers counter US pricing pressure?

10.00 am | 12 Jan 2018 |  Source: Moneycontrol.com

The economic slowdown isn't helping matters as countries in Europe are increasingly pushing price caps, rebates and procurement of drugs through p...

Hold Aurobindo Pharma, says Shahina Mukadam 

3.19 pm | 03 Jan 2018 |  Source: CNBC-TV18

Shahina Mukadam, Independent Market Expert is of the view that one may hold Aurobindo Pharma....

Hold Aurobindo Pharma, may test Rs 870: Sandeep Wagle 

3.07 pm | 03 Jan 2018 |  Source: CNBC-TV18

Sandeep Wagle of powermywealth.com is of the view that one may hold Aurobindo Pharma....

Sell Aurobindo Pharma, Indiabulls Real Estate, Adani Ports; buy Tata Motors: Mitessh Thakkar 

3.11 pm | 02 Jan 2018 |  Source: CNBC-TV18

Mitessh Thakkar of miteshthacker.com is of the view that one can sell Aurobindo Pharma, Indiabulls Real Estate and Adani Ports and can buy Tata Motors...

Aurobindo Pharma gains 2.5% on USFDA nod for Fondaparinux Sodium that prevents deep vein thrombosis

3.24 pm | 27 Dec 2017 |  Source: Moneycontrol.com

Aurobindo now has a total of 350 ANDA approvals (313 final approvals including 17 from Aurolife Pharma LLC and 37 tentative approvals) from USFDA....

Aurobindo gets USFDA nod for Fondaparinux Sodium injection

12.57 pm | 27 Dec 2017 |  Source: PTI

The approval by US Food & Drug Administration (USFDA) is for multiple strengths of Fondaparinux Sodium injection of 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg...

Buy Aurobindo Pharma, Voltas; JSPL may test Rs 240-250: Ashwani Gujral 

12.41 pm | 27 Dec 2017 |  Source: CNBC-TV18

Ashwani Gujral of ashwanigujral.com advises buying Aurobindo Pharma, Voltas and Sun Pharmaceutical Advanced Research Company....

Orchid Pharma locked at 5% upper circuit as Aurobindo, Dr Reddy's in race to buy Co

12.39 pm | 18 Dec 2017 |  Source: Moneycontrol.com

According to the media report, Aurobindo Pharma and Dr Reddy's Laboratories are the frontrunners to buy out Orchid Pharma....

News highlights of the day: Govt extends timeline for comments on data privacy till January 31

6.57 am | 18 Dec 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Prefer Aurobindo Pharma: Gaurang Shah 

2.49 pm | 11 Dec 2017 |  Source: CNBC-TV18

Gaurang Shah of Geojit Financial Services is of the view that one may prefer Aurobindo Pharma....

Buy Aurobindo Pharma; target of Rs 904: Khambatta Securities

3.45 pm | 23 Nov 2017 |  Source: Moneycontrol.com

Khambatta Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 904 in its research report dated...

Buy Aurobindo Pharma; target of Rs 1030: Centrum

4.56 pm | 22 Nov 2017 |  Source: Moneycontrol.com

Centrum is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1030 in its research report dated November 10...

Aurobindo Pharma Q2 net up 29% at Rs 780.97 cr 

8.50 am | 10 Nov 2017 |  Source: PTI

The company had posted a net profit of Rs 605.55 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a BSE filing....

Aurobindo Pharma Q2 profit seen up 15% to Rs 696 cr, operating margin may grow 110 bps 

5.26 pm | 08 Nov 2017 |  Source: CNBC-TV18

EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand...

Aurobindo Pharma Q2 PAT seen up 11.1% YoY to Rs. 672.7 cr: Kotak

5.31 pm | 13 Oct 2017 |  Source: Moneycontrol.com

Net Sales are expected to increase by 6.9 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 4035.4 crore, according to Kotak....

Buy Aurobindo Pharma; target of Rs 817: Geojit

4.09 pm | 04 Sep 2017 |  Source: Moneycontrol.com

Geojit has recommended buy rating on Aurobindo Pharma with a target price of Rs 817 in its research report dated 1 September 2017....

Buy Aurobindo Pharma; target of Rs 800: Khambatta Securities

6.05 pm | 23 Aug 2017 |  Source: Moneycontrol.com

Khambatta Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 800 in its research report dated...

Buy Aurobindo; target of Rs 825: Axis Direct

4.24 pm | 22 Aug 2017 |  Source: Moneycontrol.com

Axis Direct is bullish on Aurobindo has recommended buy rating on the stock with a target price of Rs 825 in its research report dated August 16, 2017...

1 2 3 4
Quick Links for Aurobindo Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.